Clinical Trials Browser

DNA Virus Infections, Skin Diseases, Skin Diseases, Infectious, Tumor Virus Infections, Virus Diseases, Warts, Skin Diseases, Viral, Papillomavirus Infections

NCT03981822 2024-11-27

Condylomata Acuminata, Sexually Transmitted Diseases, Skin Diseases, Skin Diseases, Infectious, Virus Diseases, Warts, Sexually Transmitted Diseases, Viral, Skin Diseases, Viral, Papillomavirus Infections

NCT06439433 2024-06-03

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

Phase 2 Completed

119 enrolled

Papillomavirus Infections

NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Phase 2 Completed

780 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

NCT04436133 2022-05-06

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

Phase 2 Completed

480 enrolled

Papillomavirus Infections

NCT02482428 2021-01-05

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Phase 2 Completed

88 enrolled 10 charts

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

NCT00586339 2020-01-03

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females

Phase 2 Completed

150 enrolled 26 charts

Gynecologic

Acquired Immunodeficiency Syndrome, Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00359619 2020-01-02

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

Phase 2 Completed

383 enrolled 28 charts

Papillomavirus Infections

NCT00231413 2019-12-12

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Phase 2 Completed

383 enrolled 30 charts

Papillomavirus Infections

NCT02631863 2019-07-08

Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)

Phase 2 Completed

60 enrolled

Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia, Papillomavirus Infections

NCT03584308 2019-05-22

Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal

Phase 2 Completed

110 enrolled

Papillomavirus Infections

NCT00309166 2018-09-17

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Phase 2 Completed

270 enrolled 14 charts

Papillomavirus Infections

NCT02724254 2018-07-20

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Phase 2 Completed

218 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

NCT00546078 2018-06-26

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

Phase 2 Completed

116 enrolled 20 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT02640820 2018-02-23

Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

Phase 2 Unknown

83 enrolled

Warts, Papillomavirus Infections

NCT02139267 2017-07-12

Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

Phase 2 Completed

72 enrolled

Gynecologic

Uterine Cervical Dysplasia, Genital Diseases, Female, Neoplasms, Uterine Diseases, Papillomavirus Infections

NCT02596243 2017-07-12

Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

Phase 2 Unknown

134 enrolled

Gynecologic

Uterine Cervical Dysplasia, Papillomavirus Infections

NCT00411749 2017-04-21

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Phase 2 Completed

107 enrolled 12 charts

Papillomavirus Infections

NCT00378560 2017-04-17

V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

Phase 2 Completed

1,021 enrolled 12 charts

Papillomavirus Infections

NCT00518336 2016-12-09

Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

Phase 2 Completed

433 enrolled 66 charts

Papillomavirus Infections

NCT00120848 2016-11-04

Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

Phase 2 Completed

776 enrolled

Papillomavirus Infections

NCT00312286 2016-09-23

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Phase 2 Terminated

538 enrolled

Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Papillomavirus Infections, Atypical Squamous Cells of the Cervix

NCT00693615 2016-09-16

Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

Phase 2 Completed

60 enrolled

Papillomavirus Infections

NCT00693966 2016-09-16

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Phase 2 Completed

210 enrolled

Papillomavirus Infections

NCT00689741 2016-09-12

Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women

Phase 2 Completed

1,113 enrolled

Papillomavirus Infections

NCT00117884 2016-08-19

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Phase 2 Terminated

240 enrolled

Gynecologic

Uterine Cervical Dysplasia, Papillomavirus Infections

NCT00520598 2015-11-26

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

Phase 2 Completed

511 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT02593968 2015-11-02

Yallaferon in Chinese Population

Phase 2 Unknown

100 enrolled

Papillomavirus Infections

NCT00551187 2015-06-08

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Phase 2 Completed

620 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Clinical Trials

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

ART-CIN_IIB

ART-VIN IIB

anal HSIL HIV-

COVE-1

CARE-1

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)

Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

Yallaferon in Chinese Population

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)